What it sells
The dynamic single-cell analysis company
Business model breakdown
Buyer: who owns the budget?
UnverifiedImmunotherapy R&D / cell therapy discovery and characterization leads at biopharma.
Trigger: what makes them buy now?
Choosing which cell therapy candidates (e.g. CAR designs) to move into clinic, understanding clinical response and keeping manufacturing consistent.
Workflow: what inputs become what output?
Load cells in nanowell grids, run time-lapse microscopy (TIMING), apply neural-network detection to quantify migration, contact, killing and survival of thousands of single cells, then retrieve cells for scRNA-seq or flow cytometry.
Economics: what it saves and how it charges
UnverifiedLikely fee-for-service assays plus instrument/platform access (cart page exists, listed on Scientist.com providers); no prices published.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.